Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer

Completed · Phase 1/Phase 2

Conditions studied: Ovarian Cancer

In brief

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by therapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody plus peripheral stem cell transplantation in treating patients who have refractory or recurrent ovarian epithelial cancer.

Key facts

Study ID

NCT00004177

Run by

Garden State Cancer Center at the Center for Molecular Medicine and Immunology

People needed

15

Starts

1999-08-01

Last updated by the study team

2011-06-22

Who can join

Age: 18 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Garden State Cancer Center — Belleville, New Jersey, United States
• St. Joseph's Hospital and Medical Center — Paterson, New Jersey, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.